Ugur Sahin
MD
CEO and Co-Founder
👥Biography 个人简介
Ugur Sahin is the co-founder and CEO of BioNTech, where he has pioneered the development of individualized mRNA cancer vaccines that encode patient-specific neoantigens to stimulate potent anti-tumor immune responses. His autogene cevumeran (BNT122) program demonstrated remarkable results in combination with pembrolizumab for melanoma, fundamentally validating the personalized mRNA cancer vaccine concept in clinical trials. He continues to advance both individualized and shared-antigen mRNA vaccine platforms across multiple tumor types.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Ugur Sahin 的研究动态
Follow Ugur Sahin's research updates
留下邮箱，当我们发布与 Ugur Sahin（BioNTech）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment